1 Dupilumab: a Review of Present Indications and Uses out Of
1 Dupilumab: a Review of Present Indications and Uses Out Of Indication Short Title: Dupilumab: New possible uses Francisco Javier Muñoz-Bellido1,2,3,4, Esther Moreno1,2,3,4, Ignacio Dávila1,2,3 1Allergy Service. Hospital Universitario de Salamanca 2Instituto Biosanitario de Salamanca, Salamanca 3Department of Biomedical and Diagnostic Sciences. University of Salamanca, Salamanca 4RETIC Asma, Reacciones adversas y Alérgicas ARADyAL Corresponding author: Esther Moreno Servicio de Alergología. Hospital Universitario de Salamanca. Paseo San Vicente 158- 182. 37007 Salamanca. Spain Email: emrodilla@usal.es This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.18176/jiaci.0682 J Investig Allergol Clin Immunol 2022; Vol. 32(2) © 2021 Esmon Publicidad doi: 10.18176/jiaci.0682 2 Abstract Recent advances in understanding T2 inflammation have broadened the diseases in which T2 inflammation can be involved. Dupilumab is a recently developed monoclonal antibody blocking the signaling of both IL-4 and IL13, two crucial cytokines of the T2 responses. New possible indications are increasingly exploring. Among them are skin diseases, such as prurigo nodularis, nummular eczema, allergic contact dermatitis, chronic hand eczema, spontaneous chronic urticaria, bullous pemphigoid, alopecia areata, and Netherton syndrome, among other several cutaneous diseases. Also, respiratory diseases, such as allergic bronchopulmonary aspergillosis, chronic eosinophilic pneumonia, and allergic rhinitis. In addition, eosinophilic gastrointestinal disorders, particularly eosinophilic esophagitis, and food allergy are two more research fields. Here we review the published data and clinical trials about the use of dupilumab in these disorders.
[Show full text]